Aflac Incorporated (AFL), headquartered in Columbus, Georgia, provides supplemental health and life insurance products. Valued at $55.1 billion by market cap, the company’s products include accident and disability, cancer expense, short-term disability, sickness and hospital indemnity, hospital intensive care, and fixed-benefit dental plans. The largest provider of supplemental insurance is expected to announce its fiscal second-quarter earnings for 2025 after the market closes on Tuesday, Aug. 5.

Ahead of the event, analysts expect AFL to report a profit of $1.72 per share on a diluted basis, down 6% from $1.83 per share in the year-ago quarter. The company beat the consensus estimates in two of the last four quarters while missing the forecast on two other occasions.

For the full year, analysts expect AFL to report EPS of $6.74, down 6.5% from $7.21 in fiscal 2024. However, its EPS is expected to rise 6.7% year over year to $7.19 in fiscal 2026. 

AFL stock has outperformed the S&P 500 Index’s ($SPX) 11.5% gains over the past 52 weeks, with shares up 13.4% during this period. However, it underperformed the Financial Select Sector SPDR Fund’s (XLF) 25.8% gains over the same time frame.

On Apr. 30, AFL reported its Q1 results, and its shares closed down more than 4% in the following trading session. Its adjusted EPS of $1.66 missed Wall Street expectations of $1.68. The company’s revenue stood at $3.4 billion, down 37.5% year over year. 

Analysts’ consensus opinion on AFL stock is cautious, with a “Hold” rating overall. Out of 16 analysts covering the stock, two advise a “Strong Buy” rating, one suggests a “Moderate Buy,” 10 give a “Hold,” and three recommend a “Strong Sell.” AFL’s average analyst price target is $105.14, indicating a potential upside of 2.8% from the current levels.